Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases

Chan, Daniel L.; Alzahrani, Nayef; Morris, David L.; Chua, Terence C.

doi:10.1016/j.suronc.2015.06.014

Cited by 23 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective analysis of clinical data from 11 studies of 1514 unresectable CRC patients with liver metastases who were treated with HAIC showed a median survival of 24 months (95% CI, 13–36 months); cumulative survival rates at 1, 2, 3, and 5 years were 76%, 51%, 29%, and 11%, respectively. [ 18 ] HAIC combined with systemic chemotherapy can better control local tumor progression, with response rates at 76%–92% and conversion resection rates up to 47%. [ 19 , 20 ]…”

Section: Discussionmentioning

confidence: 99%

Predicting survival for hepatic arterial infusion chemotherapy of unresectable colorectal liver metastases: Radiomics analysis of pretreatment computed tomography

Liu

Zhu

et al. 2022

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Objective Hepatic arterial infusion chemotherapy (HAIC) is an effective treatment for advanced unresectable colorectal cancer liver metastases (CRLM). This study was conducted to predict the efficacy of HAIC in patients with unresectable CRLM by radiomics methods based on pretreatment computed tomography (CT) examinations and clinical data. Materials and Methods A total of 63 patients were included in this study (41 in the training group and 22 in the validation group). All these patients underwent CT examination before HAIC. During the follow-up period, CT scans and laboratory examinations were performed regularly. Eighty-five radiological features were extracted from the regions of interest (ROIs) of CT images using the PyRadiomics program. The t-test and correlation were applied to select features. These features were analyzed using LASSO-Cox regression, and a linear model was developed to predict overall survival (OS). Results After reducing features by t-test and correlation test, seven features remained. After LASSO-Cox cross-validation, four features remained at λ = 0.232. They were gray level co-occurrence matrix (GLCM), gray level run length matrix (GLRLM), neighborhood gray tone difference matrix (NGTDM), and the location of the primary tumor. The C-index was 0.758 in the training group and 0.743 in the test group. Nomograms predicting 1-, 2-, and 3-year survival were established. Conclusion Our study demonstrates that a radiomics approach based on pretreatment CT texture analysis has the ability to predict early the outcome of HAIC in patients with advanced unresectable colorectal cancer with a high degree of accuracy and feasibility.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting survival for hepatic arterial infusion chemotherapy of unresectable colorectal liver metastases: Radiomics analysis of pretreatment computed tomography

Liu

Zhu

et al. 2022

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Technique Delivery of chemotherapy directly to the liver via HAI can be an effective therapy for select patients with isolated LM. [109][110][111][112][113][114][115] This requires surgical placement of a catheter into the common hepatic artery and capitalizes on the anatomical dual blood supply to the liver, in which metastases largely derive blood supply from the hepatic artery, whereas hepatic parenchyma receives both portal venous and hepatic arterial blood supply. Thus, chemotherapeutic agents can be delivered at high doses to LM via HAI, whereas relatively sparing hepatic parenchyma, where drug is effectively metabolized, and further sparing systemic toxicity.…”

Section: Topic 4/hepatic Artery Infusionmentioning

confidence: 99%

American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines

Hallemeier

Sharma

Anker

et al. 2023

Cancer

View full text Add to dashboard Cite

The liver is a common site of cancer metastases. Systemic therapy is widely accepted as the standard treatment for liver metastases (LM), although select patients with liver oligometastases may be candidates for potentially curative liver resection. Recent data support the role of nonsurgical local therapies such as ablation, external beam radiotherapy, embolization, and hepatic artery infusion therapy for management of LM. Additionally, for patients with advanced, symptomatic LM, local therapies may provide palliative benefit. The American Radium Society gastrointestinal expert panel, including members representing radiation oncology, interventional radiology, surgical oncology, and medical oncology, performed a systemic review and developed Appropriate Use Criteria for the use of nonsurgical local therapies for LM. Preferred Reporting Items for Systematic reviews and Meta‐Analyses methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established consensus methodology (modified Delphi). A summary of recommendations is outlined to guide practitioners on the use of nonsurgical local therapies for patients with LM.

show abstract

“…In addition, local therapies such as radiofrequency ablation and stereotactic body radiation therapy (SBRT) can be treatment options for resectable liver metastatic lesions [27]. In recent studies, hepatic arterial infusion and transhepatic arterial chemoembolization have been used to treat patients with mCRC with multiple liver metastases [28,29]. As a result, treatment strategies for patients with synchronous liver and CRC should be considered in conjunction with a thorough evaluation of metastatic lesions and primary tumor stages.…”

Section: Liver Metastasis In Mcrcmentioning

confidence: 99%

Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version

Park

Baik

2022

J Anus Rectum Colon

View full text Add to dashboard Cite

Stage IV colorectal cancer (CRC) has heterogeneous characteristics in tumor extent and biology. The overall survival of patients with metastatic CRC has improved with the development of multimodal treatments and new chemotherapeutic drugs. Resection of metastatic CRC is performed for liver, lung, or peritoneal metastases. Conversion surgeries to resect oligometastatic lesions have been developed with tumor regression using chemotherapeutic agents. Two-stage hepatectomy has extended the surgical indications for patients with metastatic CRC. Synchronous liver and primary tumor resection can be considered in patients with adequate conditions. Local ablation with radiotherapy can be used to treat lung metastasis. In the treatment of patients with CRC with peritoneal metastasis, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy can be considered. Surgical treatments should be performed in patients with symptomatic primary tumors with unresectable metastasis. However, primary tumor resection in patients with asymptomatic CRC with synchronous, unresectable metastases did not show overall survival benefits in recent studies. Therefore, the treatment of metastatic CRC is challenging due to the variable tumor extent and heterogenous characteristics. Tailored surgical treatments and multidisciplinary approaches may improve survival and the quality of life in patients with metastatic CRC.

show abstract

Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases

Cited by 23 publications

References 49 publications

Predicting survival for hepatic arterial infusion chemotherapy of unresectable colorectal liver metastases: Radiomics analysis of pretreatment computed tomography

Predicting survival for hepatic arterial infusion chemotherapy of unresectable colorectal liver metastases: Radiomics analysis of pretreatment computed tomography

American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines

Recent Advance in the Surgical Treatment of Metastatic Colorectal Cancer-An English Version

Contact Info

Product

Resources

About